FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients

View source ↗

Summary

FDA approves TREGZI, the first regulatory T cell–based immunotherapy to improve chronic GVHD-free survival in adults undergoing allo-HSCT for blood cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blood Cancer
• Graft-versus-host Disease

Drugs mentioned

• TREGZI

Snippet

The U.S. Food and Drug Administration today approved TREGZI, the first regulatory T (Treg) cell-based immunotherapy for improving chronic graft-versus-host disease (GVHD)-free survival in adult patients with blood cancers undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).